Dual targeting of HER3 and MEK may overcome HER3-dependent drug-resistance of colon cancers

Although the medical treatment of colorectal cancer has evolved greatly in the last years, a significant portion of early-stage patients develops recurrence after therapies. The current clinical trials are directed to evaluate new drug combinations and treatment schedules. By the use of patient-deri...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:Oncotarget
Glavni autori: Bon, Giulia, Loria, Rossella, Amoreo, Carla Azzurra, Verdina, Alessandra, Sperduti, Isabella, Mastrofrancesco, Arianna, Soddu, Silvia, Diodoro, Maria Grazia, Mottolese, Marcella, Todaro, Matilde, Stassi, Giorgio, Milella, Michele, De Maria, Ruggero, Falcioni, Rita
Format: Artigo
Jezik:Inglês
Izdano: Impact Journals LLC 2016
Teme:
Research Paper
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5752456/
https://ncbi.nlm.nih.gov/pubmed/29312543
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.11400
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items